Last week, Leerink Partners healthcare analysts Geoffrey Porges, Seamus Fernandez, and Paul Matteis dropped by the STAT offices for a conversation with biotech reporters Damian Garde and Adam Feuerstein.
In this edited excerpt, the Leerink analysts discuss the evolving role of the sell-side analyst on Wall Street. Price targets and stock ratings — though widely ridiculed — still matter, they say. And they have answers to the critics who accuse sell-siders of being feckless sycophants willing to do or say anything to stay in the good graces of investment-banking clients.
Part two of this conversation, focused on industry trends and Trump’s FDA, will be coming later this week.
